<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02438748</url>
  </required_header>
  <id_info>
    <org_study_id>B2014:102</org_study_id>
    <nct_id>NCT02438748</nct_id>
  </id_info>
  <brief_title>Biological Markers of Treatment Response to Repetitive Transcranial Magnetic Stimulation for Depression</brief_title>
  <official_title>The Role of Biological Stress Markers in Predicting Treatment Response to Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine whether biological stress markers (Oxidized&#xD;
      Phosphatidylcholines and Oxylipins) in the blood can be used to predict the efficacy of rTMS&#xD;
      in the treatment of major depressive disorder (MDD). It is our goal to identify biomarkers&#xD;
      that may be used to determine which patients will benefit from rTMS treatment. A second&#xD;
      objective of this study is to measure any changes in stress markers that occur across the&#xD;
      course of rTMS therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      250 patients who have been prescribed repetitive transcranial magnetic stimulation (rTMS)&#xD;
      therapy for the treatment of major depressive disorder will be recruited for this study.&#xD;
      Prior to undergoing rTMS, patients will give a small blood sample. An additional blood sample&#xD;
      will be given upon completion of rTMS treatment. 60 healthy control individuals will also be&#xD;
      recruited to provide a one-time blood sample for comparison. Control individuals will not&#xD;
      receive rTMS treatment.&#xD;
&#xD;
      Blood samples will be analysed for levels of Oxidized Phosphatidylcholines and Oxylipins. The&#xD;
      investigators wish to determine whether there is a difference in the pre-treatment levels of&#xD;
      stress markers between individuals who ultimately respond to rTMS and those who do not.&#xD;
      Additionally, the investigators wish to determine whether there is a change in stress markers&#xD;
      as a result of rTMS treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Oxidized Phosphatidylcholines in plasma</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change in Oxidized Phosphatidylcholine levels in blood plasma pre- and post-repetitive transcranial magnetic stimulation (rTMS) treatment for depression.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Individuals undergoing Repetitive Transcranial Magnetic Stimulation treatment for major depressive disorder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy age-, and sex-matched control individuals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>A non-invasive method of brain stimulation.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10ml of blood will be extracted at each collection. Patients will give two samples. Controls&#xD;
      will give one sample. Following collection, blood samples will be spun to separate and&#xD;
      extract plasma. The amount of oxidized phosphatidylcholines in the plasma will then be&#xD;
      quantified.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        250 patients with Major Depressive Disorder who have been deemed eligible for rTMS&#xD;
        treatment. Eligible persons will be identified by a psychiatrist from among patients at the&#xD;
        outpatient Neuromodulation and Neuropsychiatric Unit at St Boniface Hospital. 60 healthy&#xD;
        control individuals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patient Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a major depressive episode&#xD;
&#xD;
          -  Not actively receiving psychotherapy&#xD;
&#xD;
        Patient Exclusion Criteria:&#xD;
&#xD;
          -  History of a psychotic episode&#xD;
&#xD;
          -  History of neurological illness&#xD;
&#xD;
          -  Head injury&#xD;
&#xD;
          -  Active alcohol or substance abuse&#xD;
&#xD;
          -  History of a seizure disorder&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
        Control Subject Exclusion Criteria:&#xD;
&#xD;
          -  History of depression or psychiatric illness&#xD;
&#xD;
          -  History of a psychotic episode&#xD;
&#xD;
          -  History of neurological illness&#xD;
&#xD;
          -  Head injury&#xD;
&#xD;
          -  Active alcohol or substance abuse&#xD;
&#xD;
          -  History of a seizure disorder&#xD;
&#xD;
          -  Pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mandana Modirrousta, MD PhD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3P2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 6, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxidized Phosphatidylcholines</keyword>
  <keyword>Oxylipins</keyword>
  <pending_results>
    <submitted>October 1, 2021</submitted>
    <returned>October 29, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

